Summary Ormaplatin (also known as tetraplatin) is a platinum-containing analogue which has recently undergone clinical trials. Ormaplatin may undergo conversion to dichloro(D,L-trans)-1,2-diaminocyclohexaneplatinum(II) [PtCl2(trans-dach)]. The cisplatin-resistant murine lymphoma cell lines E8 and E5, were found to be cross-resistant to ormaplatin and PtCl2(trans-dach). We found an inverse rank correlation between drug resistance and drug accumulation for PtCl2(trans-dach) similar to our previous findings with cisplatin; however, accumulation of ormaplatin in the resistant cells was increased. Ormaplatin cytotoxicity appears to result primarily from extracellular conversion to PtCl2(trans-dach), since ormaplatin cytotoxicity was decreased under conditions where extracellular conversion to PtCl2(trans-dach) was minimised. Co-incubation with different inhibitors of energy metabolism resulted in a 65-70% increase in PtCl2(trans-dach) accumulation in the parental cell line Ri.1 and a 113-307% increase in the resistant cell line E5 which suggests that the decrease in accumulation in E5 may be at least partly energy dependent. We conclude from these findings that crossresistance to ormaplatin is associated with an energy-dependent decreased accumulation of PtCl2(trans-dach) in these cisplatin-resistant cell lines.
Although cis-diamminedichloroplatinum(II) (cisplatin) has significant activity against a broad range of human malignancies, cisplatin-based chemotherapy is frequently not curative. The development of resistance to cisplatin at a cellular level is believed to be a major obstacle to improving the outcome with cisplatin-based chemotherapy. Experimental models of cisplatin resistance have implicated multiple mechanisms including decreased drug accumulation, elevated glutathione and metallothionein levels, increased DNA repair and increased tolerance of DNA damage (Andrews and Howell, 1990; Shellard et al., 1993) .
One approach to circumventing cisplatin resistance is the development of platinum-containing analogues that are not cross-resistant. Ormaplatin is one such analogue that was not cross-resistant in the initial studies in L1210 and P388 leukaemias (Anderson et al., 1986; Wilkoff et al., 1987) or in cisplatin-resistant human lung cancer cell lines (Ohmori et al., 1993) . Other studies have revealed that although ormaplatin has a different pattern of sensitivity compared with cisplatin or carboplatin, partial cross-resistance to ormaplatin may occur (Hills et al., 1989; Perez et al., 1991; Teicher et al., 1991; Bhuyan et al., 1991; Kelland et al., 1992) . The mechanisms of cross-resistance to ormaplatin have not been extensively studied, but may be complex (Parker et al., 1993) . Ormaplatin has also been found to be less nephrotoxic than cisplatin (Smith et al., 1988) , but neurotoxicity has been a significant problem in early clinical trials (Schilder et al., 1994; O'Rourke et al., 1994) .
Ormaplatin is a platinum (IV) compound which can be reduced to the platinum (II) compound dichloro(D,L,-trans)-1,2 -diaminocyclohexaneplatinum (II) [PtCl2(trans -dach)] (Eastman, 1987; Gibbons et al., 1989) (Figure 1 ). It has been demonstrated that ormaplatin is converted to PtCl2(trans-dach) in both tissue culture media and rat plasma (Gibbons et al., 1989; Chaney et al., 1990) . Although it has been thought that this reduction could also occur intracellularly (Eastman, 1987) , recent work has revealed unexpected intracellular biotransformation pathways for ormaplatin which do not result in formation of PtCl2(transdach) (Chaney et al., 1991) . Our laboratory has previously described a series of cisplatin-resistant cell lines (E8 and E5) derived from the murine lymphoma cell line, RI.1. In these cisplatin-resistant cell lines there is an inverse rank correlation between the level of resistance and intracellular drug accumulation (Kawai et al., 1990) . The mechanism of decreased accumulation in cisplatin-resistant cell lines is poorly understood. It is also unclear whether cisplatin or other platinum-containing analogues cross the plasma membrane by passive diffusion or by a mediated route. In this paper we demonstrate crossresistance to ormaplatin in these cell lines, which is associated with decreased accumulation of PtCl2(trans-dach) but not ormaplatin. The mechanism of decreased accumulation and the factors affecting the reduction of ormaplatin to PtCl2(trans-dach) were also investigated.
Materials and methods

Cell lines
The murine T cell lymphoma cell line Rl.1 and its cisplatinresistant variants, E8 and E5, have been described previously (Kawai et al., 1990) . These resistant cell lines were selected by continuous exposure to cisplatin and exhibit decreased accumulation of cisplatin. All cell lines were grown as monolayers in RPMI 1640 medium (Gibco, Burlington, Ontario, Canada) supplemented with 10% fetal bovine serum (FBS) (Hyclone, Logan, Utah, USA), 100 units ml-' penicillin and 100 jug ml-' streptomycin sulphate. All The level of drug resistance was examined using the MTT assay as previously described (Kawai et al., 1990; Carmichael et al., 1987) with minor modifications. Briefly, cells (4000-5000) seeded in microtitre plates were allowed to attach for 4 h and then exposed to drug for 1 or 96 h at 37°C. For the 1 h exposure assay, cells were exposed to drug, then medium was aspirated and the wells washed twice with ice-cold PBS. Cells were then incubated in fresh medium for 96 h. After 96 h MTT (50 MI of 2 mg ml-') was added to each well and plates were incubated for another 4 h. Plates were centrifuged, then wells were aspirated, 100 !l dimethyl sulphoxide was added to each well and absorbance at a wavelength of 540 nm measured. During the 96 h drug exposures the medium was not changed, and the drug was not washed out before the addition of MTT.
Drug accumulation
Cells were seeded in 60 mm tissue culture dishes 2 days before examining drug accumulation. At the time of the experiments cells were in exponential phase and approximately 50% confluent. Medium was aspirated and dishes washed twice with prewarmed PBS before adding transport buffer (phosphate-buffered saline with 11 mM glucose, pH 7.3) containing radiolabelled drug. Incubations of less than 10 min duration took place in a 37°C oven and for longer incubations dishes were returned to the tissue culture incubator (37°C, 5% carbon dioxide). Incubations were terminated by rapidly aspirating buffer and washing three times in ice-cold PBS. Cells were digested in 3 ml of 0.5 M sodium hydroxide overnight. A 10 ,ul aliquot was taken for duplicate protein estimation by the method of Bradford modified for microtitre plate assay (Bradford, 1976; Simpson and Sonne, 1982 Gibbons et al., 1989) . In the concentration range we were using PtCl2(transdach) was not detectable with ultraviolet photometric detection (HPLC-UV) as it has much lower absorptivity than ormaplatin at 254 nm (Bhuyan et al., 1991) . Therefore, the decrease in the ormaplatin peak on HPLC-UV was routinely used to estimate the percentage reduction of ormaplatin. Simultaneous HPLC analysis using a radiochemical detector revealed that the combined ormaplatin and PtCl2(trans-dach) peaks did not decrease under any of the experimental conditions we employed which is consistent with the decreases in the ormaplatin peak detected by HPLC-UV being due to ormaplatin being converted to PtCl2(trans-dach).
[3H]PtCl2(trans-dach) (2.5 tM) was incubated in various transport buffers in the presence or absence of cells for 30 min at 37°C in the tissue culture incubator. After this incubation an aliquot of the buffer was centrifuged in an airdriven ultracentrifuge (Beckman) for 15 s to remove any cells or debris and then 50 pl was injected for HPLC analysis.
Extracellular thiol concentration
Sulfhydryl content was determined using a modification of the Ellman method (Ellman, 1980) . Cells were seeded in 100 mm tissue culture dishes two days before experiments at which time they were in exponential phase. Cells were incubated in 5 ml transport buffer with or without cystine for 1 h at 37°C in the tissue culture incubator. After incubation 1.5 ml of the buffer was removed and centrifuged for 2 min at 2000 r.p.m. in a tabletop centrifuge to remove any floating cells. An aliquot of 1.5 ml of the buffer was mixed with 1.5 ml of 0.2 M potassium phosphate-10 mM EDTA, pH 8.0. Absorbance at 412 nm was measured, then 210 ,ul of 6 mM 5,5'-dithiobis (2-nitrobenzoic acid) was added and the increase in absorbance was measured after 5 min. The sulfhydryl content was calculated from the increase in absorbance using cysteine as a standard.
Results
Drug resistance
In the 4 day continuous exposure assays there was partial cross-resistance to ormaplatin but marked cross-resistance to carboplatin, relative to the resistance to cisplatin ( Table I) . The degree of cross-resistance to the d and 1 isomers of ormaplatin was similar to the racemic mixture, though the 1 isomer was less potent than the d isomer. As expected based on the known conversion of ormaplatin to PtCl2(trans-dach) in tissue culture media (Gibbons et al., 1989) , PtCl2(transdach) gave very similar results to ormaplatin. In the 1 h exposure assays the fold resistance to cisplatin was less than in the 4 day assays, but the cross-resistance to ormaplatin was greater in the 1 h assay particularly in E5. In a study of cisplatin-resistant human ovarian cell lines, it was proposed that there are two platinum-resistant phenotypes; one with high levels of resistance to cisplatin and carboplatin and more moderate resistance to ormaplatin, and the other with low levels of resistance to cisplatin and carboplatin and comparatively high levels of resistance to ormaplatin (Perez et al., 1991 (Figure 2 ). This was confirmed by experiments in which accumulation of ormaplatin in PBS over 5 min revealed a 28-66% increase in E5 in the 1-10 Mm concentration range (data not shown). In order to determine which component of RPMI medium modulated the accumulation of ormaplatin, accumulation was measured in different PBS buffers each supplemented with a component of RPMI medium. Only the addition of the amino acid cystine resulted in decreased accumulation of radiolabelled drug similar to that seen with complete RPMI medium. When cells were exposed to ormaplatin the accumulation of radiolabelled drug in the presence of PBS supplemented with cystine was similar to the accumulation of PtCl2(trans-dach), with an inverse rank correlation with the level of resistance (Figure 2 ). This raised the possibility that in the presence of cystine, ormaplatin was being converted to PtCl2(trans-dach), although previous work had suggested that cystine was not one of the components of RPMI medium which could convert ormaplatin to PtCl2(trans-dach) (Gibbons et al., 1989) .
Reduction of ormaplatin in transport buffer
In order to determine the fate of ormaplatin in different transport buffers HPLC analysis was performed. The percentage of ormaplatin remaining at 30 min was calculated (Table II) . There was little conversion to PtCl2(trans-dach) in PBS and glucose but in the presence of cells there was an unexpected 40-50% reduction. The addition of cystine resulted in a 40% decrease and in the presence of RI.1 and E5 cells there was a 64% and 91% decrease respectively. The effect of cystine was also demonstrated by the fact that in RPMI medium the reduction of ormaplatin was approximately 20% greater than in RPMI medium without cystine. The most extensive reduction of ormaplatin in the absence of Transport of PtC'l(trans-dach) As accumulation of PtCl2(trans-dach) or ormaplatin under conditions in which it was predominantly converted to PtCl2(trans-dach), was reduced in the platinum-resistant cells the transport of PtCl2(trans-dach) was studied in more detail. The accumulation of 2.5 JIM PtCl2(trans-dach) in E5 was 37-53% less than in Ri.1 over the first hour (Figure 3) . From 2.5 up to 100 JgM there is a 40-50% reduction in the 5 min accumulation of PtCl2(trans-dach) in E5 (Figure 4 ). The increase in accumulation with increasing concentration is linear in RI.1. In E5 there is some deviation from linearity at 100 yiM but the low solubility of this compound prevented testing at higher concentrations to determine whether there really was saturation. Although these studies were done over a relatively short time interval (5 min), they do not necessarily represent zero-trans conditions which are ideally required to measure drug influx. However, efflux studies demonstrated that there was no increase in efflux in E5 that could account for the lower drug accumulation in these cells ( Figure 5 ). Hence these results are more consistent with decreased influx rather than increased efflux.
Effect of temperature, sodium, metabolic inhibitors and platinum-containing analogues on the accumulation of PtCl2(trans-dach)
The 5 min accumulation of 2. (--0-- Time (min) Figure 5 Efflux of PtCl2(trans-dach) from Ri.1 (-a-) and E5 (--0--). R1. 1 was loaded with 2.5 IIM [3H]PtCl2(trans-dach) and E5 with a 3.75,M, each for 15min. Release of drug into drug-free buffer was measured over 30min. Points are the means+s.d. of three experiments. When the s.d. was less than the symbol size, error bars were omitted. cytotoxicity that is seen in PBS could be largely owing to the PtCl2(trans-dach) that was formed in the extracellular buffer, and it is less than in media with serum as there is less PtCl2(trans-dach) formed in PBS. These results suggest that the ormaplatin that crosses the plasma membrane without prior reduction is less cytotoxic than ormaplatin which is reduced to PtCl2(trans-dach) extracellularly. In fact ormaplatin that is not reduced extracellularly may not result in any significant cytotoxicity, at least in the cell lines we have examined. These findings are consistent with the findings of Chaney and colleagues who demonstrated in an L1210 cell line that most of the ormaplatin was not converted to PtCl2(trans-dach) intracellularly but to two other transformation products that were not reactive with DNA (Chaney et al., 1991) . Our results differ from the report by Eastman in an L1210 cell line where he found increased ormaplatin cytotoxicity in Hanks' balanced salt solution, and postulated that ormaplatin could be reduced to PtCl2(trans-dach) intracellularly (Eastman, 1987) . In another study using the same L1210 cell lines the cytotoxicity of ormaplatin in Hanks' balanced salt solution was increased by the addition of glutathione which increased extracellular conversion to PtCl2(trans-dach) (Kido et al., 1994) . All these studies support the hypothesis that ormaplatin requires reduction to PtCl2(trans-dach) for biological activity.
Our HPLC results emphasise the importance of determining the amount of ormaplatin reduction that occurs under the conditions used in cytotoxicity or transport studies. It had not been previously appreciated that there would be an increase in the reduction of ormaplatin in the presence of cells, nor that cystine in the media may contribute to this reduction of ormaplatin. The increased formation of thiols in the extracellular buffer in the presence of cystine is probably due to the uptake of cystine by the cells, its rapid conversion to cysteine and subsequent efflux out of the cells, as has been demonstrated in skin fibroblasts (Bannai and Ishii, 1980) . The striking difference in the concentration of extracellular thiols between sensitive and resistant cells can be at least partly explained by the fact that there is increased cystine uptake in the resistant cells (D Rischin and V Ling, manuscript in preparation). Previous reports of the percentage of ormaplatin remaining after a 30 min incubation in RPMI medium with 15% fetal bovine serum have ranged from 5% to over 80% (Bhuyan et al., 1991; Gibbons et al., 1989) . Our result of 32% was obtained with a lower percentage of fetal bovine serum, 10%. These variable results may be caused by different sources of serum.
Similar to our previous findings with cisplatin (Kawai et al., 1990) there was an inverse rank correlation between the level of ormaplatin or PtCl2(trans-dach) resistance and the accumulation of PtCl2(trans-dach), suggesting that decreased accumulation may play a role in the cross-resistance to these drugs in the platinum-resistant cell lines. However, it cannot fully explain the dramatic increase in ormaplatin resistance between E8 and E5 seen in the 1 h exposure assays. Ormaplatin accumulation was actually increased in the resistant cells which provides further indirect support for the notion that PtCl2(trans-dach) rather than ormaplatin accumulation contributes to ormaplatin sensitivity.
Studies in L1210 models have demonstrated that the cisplatin-resistant variants have only minor levels of crossresistance to ormaplatin or PtCl2(trans-dach) (Richon et al., 1987; Kraker and Moore, 1988; Goddard et al., 1991; Nicolson et al., 1992) , which in turn is associated with only slight decreases in the accumulation of PtCl2(trans-dach) (Richon et al., 1987; Nicholson et al., 1992; Gibbons et al., 1990) . However, other cisplatin-resistant variants have more significant levels of cross-resistance to ormaplatin (Teicher et al., 1991; Bhuyan et al., 1991; Kelland et al., 1992) . L1210 variants selected in PtCl2(trans-dach) or ormaplatin have demonstrated significantly decreased accumulation of PtCl2trans-dach) (Richon et al., 1987; Nicolson et al., 1992; Gibbons et al., 1990) . The mechanism of decreased accumulation of PtCl2(trans-dach) has not been studied extensively. One recent study found no difference in efflux (Nicolson et al., 1992) . We also found that there was no apparent increase in efflux in the resistant cells. The decrease in accumulation was detectable at low concentrations and over short time intervals (2-5 min). Most interestingly, inhibition of energy metabolism resulted in increased accumulation with a more marked effect in the resistant cells. There did not appear to be any decrease in efflux in the presence of sodium azide, as would be expected if there was an energy-dependent efflux transporter involved. Our results would appear to favour decreased influx as the mechanism of decreased accumulation. One possibility is that there is an energy-dependent restriction to PtCl2(trans-dach) influx which is greater in the resistant cells, so that in the absence of energy the accumulation between the sensitive and the resistant cells is decreased or abolished. However, as increased accumulation following inhibition of energy metabolism is more characteristic of an efflux transporter, the possibility of increased efflux in the resistant cells cannot be excluded despite the fact that we could not demonstrate any such increase. It is interesting to note that in some multidrug-resistant cell lines that overexpress P-glycoprotein reduced influx has been reported (Sirotnak et al., 1986; Ramu et al., 1989) . It has been postulated that the influx of drug can be altered by the presence of an efflux pump such as Pglycoprotein under certain circumstances (Demant et al., 1990) . The effect of energy depletion on PtCl2(trans-dach) transport has not been previously reported. In our cell lines neither sodium azide nor dinitrophenol altered cisplatin accumulation (data not shown). Conflicting results have been reported in studies examining the effect of energy depletion on cisplatin accumulation in human ovarian carcinoma cell lines. Andrews et al. (1988) found that a combination of inhibitors of oxidative phosphorylation and inhibitors of glycolysis resulted in a decrease in cisplatin accumulation in both sensitive and resistant cells, while Sharp et al. (1995) demonstrated an increase in cisplatin accumulation in both sensitive and resistant cells under similar conditions.
As to whether there is a mediated component to (Bernal et al., 1990) and the overexpression of a 36 kDa plasma membrane protein in a cisplatin-resistant human ovarian carcinoma cell line (Sharp et al., 1995) . It is not known at the present time whether any of these membrane proteins have a role in mediating the decreased accumulation of platinum that is commonly present in cisplatin-resistant cell lines. In summary our cisplatin-resistant cell lines are crossresistant to ormaplatin and PtCl2(trans-dach) and this is associated with an energy-dependent decreased accumulation of PtCl2(trans-dach). Ormaplatin cytotoxicity appears to result primarily from extracellular conversion to PtCl2(transdach), since ormaplatin cytotoxicity was decreased under conditions where extracellular conversion to PtCl2(trans-dach) was minimised. In plasma rapid conversion of ormaplatin to PtCl2(trans-dach) occurs but when ormaplatin is given by other routes, e.g. intraperitoneally (Plaxe et al., 1993) , the rate of extracellular conversion to PtCl2(trans-dach) may determine the intracellular levels of biologically active drug.
Abbreviations cisplatin, cis-diamminedichloroplatinum(II); ormaplatin, tetrachloro(D,L-trans)-1 ,2-diaminocyclohexaneplatinum(II), also called tetraplatin; PtCl2(trans-dach), dichloro(D,L-trans)-1 ,2-diaminocyclohexaneplatinum(II); MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; PBS, phosphate-buffered saline; HPLC, high-pressure liquid chromatography.
